<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02121717</url>
  </required_header>
  <id_info>
    <org_study_id>CGZ301</org_study_id>
    <nct_id>NCT02121717</nct_id>
  </id_info>
  <brief_title>Study of Chiglitazar Compare With Placebo in Type 2 Diabetes Patients</brief_title>
  <acronym>CMAP</acronym>
  <official_title>Phase III Study of Chiglitazar in Patients With Type 2 Diabetes Mellitus and Insufficient Glycemic Control Despite Diet and Exercise -- A Multicenter, Randomized, Double-Blind, and Placebo-Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chipscreen Biosciences, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chipscreen Biosciences, Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of Chiglitazar, compare with
      placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The efficacy and safety will be compared between Chiglitazar and placebo after treatment of
      24 weeks. The long term efficacy and safety of Chiglitazar will be evaluated after 52 weeks
      treatment.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in HbA1c from baseline after 24 weeks of treatment</measure>
    <time_frame>24 weeks</time_frame>
    <description>The change of HbA1c at week 24 from baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in HbA1c from baseline for patients with a baseline HbA1c &gt;=8.5%</measure>
    <time_frame>24 weeks</time_frame>
    <description>The change of HbA1c at week 24 from baseline for patients with a HbA1c &gt;=8.5% at baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HbA1c from baseline in patients with a baseline HbA1c &lt; 8.5%</measure>
    <time_frame>24 weeks</time_frame>
    <description>The change of HbA1c at week 24 from baseline for patients with a HbA1c &lt; 8.5% at baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HbA1c from baseline</measure>
    <time_frame>12 weeks</time_frame>
    <description>The change of HbA1c at week 12 from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HbA1c from baseline</measure>
    <time_frame>52 weeks</time_frame>
    <description>The change of HbA1c at week 52 from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients that attained target HbA1c &lt;7.0%</measure>
    <time_frame>24 weeks</time_frame>
    <description>Percentage of patients whose HbA1c at week 24 are &lt; 7.0%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients whose HbA1c lowered by at least 0.5%</measure>
    <time_frame>24 weeks</time_frame>
    <description>Percentage of patients whose change of HbA1c at week 24 from baseline are &gt;= 0.5%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fasting plasma glucose from baseline</measure>
    <time_frame>12,24 and 52 weeks</time_frame>
    <description>The change of fasting plasma glucose at week 12 and 24 from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 2-h postprandial glucose (2hPPG) from baseline</measure>
    <time_frame>12, 24 and 52 weeks</time_frame>
    <description>The change of 2-h postprandial glucose (2hPPG) at week 12, 24 and 52 from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in total cholesterol (TC) from baseline</measure>
    <time_frame>12, 24 and 52 weeks</time_frame>
    <description>The change of total cholesterol (TC) at week 12, 24 and 52 from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in triglyceride from baseline</measure>
    <time_frame>12,24 and 52 weeks</time_frame>
    <description>The change of triglyceride at week 12, 24 and 52 from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in high density lipoprotein cholesterol (HDL-C)from baseline</measure>
    <time_frame>12, 24 and 52 weeks</time_frame>
    <description>The change of high density lipoprotein cholesterol (HDL-C) at week week 12, 24 and 52 from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in low density proprotein cholesterol (LDL-C) from baseline</measure>
    <time_frame>12, 24 and 52 weeks</time_frame>
    <description>The change of low density lipoprotein cholesterol (LDL-C) at week 12, 24 and 52 from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in free fatty acid (FFA) from baseline</measure>
    <time_frame>12, 24 and 52 weeks</time_frame>
    <description>The change of free fatty acid (FFA) at week 12, 24 and 52 from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fasting plasma insulin from baseline</measure>
    <time_frame>12, 24 and 52 weeks</time_frame>
    <description>The change of fasting plasma insulin at week 12, 24 and 52 from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin sensitivity assessed by the homeostatic model assessment (HOMA) at 12,24 and 52 weeks, compared with that of baseline</measure>
    <time_frame>12, 24 and 52 weeks</time_frame>
    <description>The change of insulin sensitivity at week 12, 24 and 52 from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in blood pressure from baseline</measure>
    <time_frame>24 weeks</time_frame>
    <description>The change of blood pressure at week 24 from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients who use rescue therapy</measure>
    <time_frame>52 weeks</time_frame>
    <description>The percentage of patients who use rescue therapy during the 52 weeks of treatment</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">534</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients administrate Chiglitazar 32mg once daily for 52 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients administrate Chiglitazar 48mg once daily for 52 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients administrate placebo for 24 weeks.From week 25 to 52, patients are randomly switched to Arm 1 and Arm 2, and receive the treatment accordingly.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chiglitazar</intervention_name>
    <description>Take orally</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_label>Arm 3</arm_group_label>
    <other_name>CS038</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Take orally</description>
    <arm_group_label>Arm 3</arm_group_label>
    <other_name>Plb</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Meet the WHO Diagnostic Criteria for Type 2 Diabetes (published on 1999);

          2. HbA1c≥ 7.5% and ≤ 10.0% after control of diet and exercises;

          3. Male and female,age between 18 and 70 years;

          4. BMI between 18.5-35kg/m2;

          5. Willing to be assigned to any treatment arm and sign inform consent.

        Exclusion Criteria:

          1. Type 1 diabetes;

          2. Treated by oral or injective antidiabetic drug before screening, including insulin and
             herb;

          3. Fasting plasma glucose &gt; 13.3 mmol/L (240 mg/dL);

          4. Resistant hypertension [blood pressure above the goal despite adherence to at least 3
             optimally dosed antihypertensive medications (including diuretic) of different
             classes,or blood pressure is controlled to below the goal by at least 4 different
             classes of drugs];

          5. Plasma triglyceride &gt; 500 mg/dL (5.65 mmol/L);

          6. Is treating by fibrates;

          7. History of diabetic ketoacidosis,diabetic hyperglycemic hyperosmolar syndrome,lactic
             acidosis, diabetic hypoglycemia; or is currently combined with retinopathy, diabetic
             nephropathy and diabetic neuropathy;

          8. Had transient ischemic attack,cerebrovascular accident or unstable angina in the past
             6 months;

          9. History of myocardial infarction or had conducted coronary angioplasty or coronary
             artery bypass graft surgery;

         10. Heart failure (NYHA classification Stage III or IV), or left ventricular hypertrophy
             indicated by ECG;

         11. Hepatic diseases such as hepatocirrhosis, active hepatitis,aspartate aminotransferase
             or alanine aminotransferase &gt; 2.5 fold of the upper limit of the normal range;

         12. Kidney diseases or serum creatinine exceed the normal range: male &gt; 133 μmol/L or
             female &gt;108 μmol/L;

         13. Had malignancy in the past 5 years, not including basal cell carcinoma;

         14. Had or is currently receiving treatment that can alter blood glucose metabolism,
             including but not limited to diuretic,hormone (corticotropin or steroids),beta
             blockers;

         15. Have the diseases that can alter blood glucose metabolism, including but not limited
             to active hepatitis, hyperthyroidism,or adrenal tumors;

         16. Edema with unknown reason;

         17. Alcohol or drug addiction;

         18. Had participated other drugs' clinical trials in the 3 months before screening;

         19. Pregnant or lactic women; or women of childbearing age who are not able to or is not
             willing to conduct contraception;

         20. Any condition that make investigator consider the subject is not suitable to
             participate the trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Linong Ji, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University People's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Peking University Shougang Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China Meitan General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100028</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking University People's Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The 306th Hospital of PLA</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100101</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Chongqing Medical University</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400016</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Chongqing Medical University</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400016</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chongqing Three Gorges Central Hospital</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>404000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cangzhou's Central Hospital</name>
      <address>
        <city>Cangzhou</city>
        <state>Hebei</state>
        <zip>061110</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harrison International Peace Hospital</name>
      <address>
        <city>Hengshui</city>
        <state>Hebei</state>
        <zip>053000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Third Hospital of Hebei Medical University</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>050051</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tangshan Gongren Hospital</name>
      <address>
        <city>Tangshan</city>
        <state>Hebei</state>
        <zip>063000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Ha'erbin Medical University</name>
      <address>
        <city>Ha'erbin</city>
        <state>Heilongjiang</state>
        <zip>150081</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhongnan Hospital of Wuhan University</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430071</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chenzhou First People's Hospital</name>
      <address>
        <city>Chenzhou</city>
        <state>Hunan</state>
        <zip>423000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baogang Hospital of Inner Mongilia</name>
      <address>
        <city>Baotou</city>
        <state>Inner Mongolia</state>
        <zip>014010</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The people's Hospital of Jiangsu Province</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Affiliated Hospital of Xuzhou Medical College</name>
      <address>
        <city>Xuzhou</city>
        <state>Jiangsu</state>
        <zip>221000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Affiliated Hospital of Qingdao Medical University</name>
      <address>
        <city>Qingdao</city>
        <state>Shandong</state>
        <zip>266071</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhongshan Hospital Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Xin Hua Hospital Affiliated to Shanghai Jiaotong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200092</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Central Hospital of Yangpu District of Shanghai</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of The 4th Military Medical University</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Huaxi Hopsital of Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The General Hospital of Tianjin Medical University</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300052</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 22, 2014</study_first_submitted>
  <study_first_submitted_qc>April 22, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 23, 2014</study_first_posted>
  <last_update_submitted>January 23, 2018</last_update_submitted>
  <last_update_submitted_qc>January 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chiglitazar,diabetes,type 2 diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

